Linking Toxicity to the Target
Mené sur 4 554 patientes atteintes d'un cancer du sein opérable, cet essai évalue l'association entre l'efficacité d'un traitement adjuvant à base de taxanes et une neuropathie
In Journal of Clinical Oncology, Schneider et al report a study of taxane-induced neuropathy and clinical outcomes in a large randomized trial in early-stage breast cancer. The landmark E1199 trial established the optimal taxane and schedule (once-per-week paclitaxel or three-times-per-week docetaxel) to be delivered after a standard anthracycline regimen as adjuvant therapy in node-positive or high-risk node-negative breast cancer. Theauthors correlated the development of neuropathy within 7 months of random assignment among patients who received at least one dose of a taxane with recurrence-free survival, disease-free survival (DFS), and overall survival. No association was found between the development of grades...